2-[Methyl(2-thienylmethyl)amino]ethanol | 121489-19-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[Methyl(2-thienylmethyl)amino]ethanol
• 英文别名: 2-[methyl(thiophen-2-ylmethyl)amino]ethanol
• CAS: 121489-19-8
• 化学式: C₈H₁₃NOS
• mdl: MFCD12189932
• 分子量: 171.263
• InChiKey: CBIRFVUGJPCMHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  51.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[Methyl(2-thienylmethyl)amino]ethanol 在 哌啶乙酸盐 、 三乙胺 作用下， 以 氯仿 、 苯 为溶剂， 反应 10.0h， 生成 2-[1-(3-Nitro-phenyl)-meth-(E)-ylidene]-3-oxo-butyric acid 2-(methyl-thiophen-2-ylmethyl-amino)-ethyl ester
  参考文献：
  名称：

  新型的2-氨基-1,4-二氢吡啶类钙拮抗剂。二。在3-和/或5-位具有N，N-二烷基氨基烷氧基羰基的2-氨基-1，4-二氢吡啶衍生物的合成和降压作用。

  摘要：

  合成了在3和/或5位上含有N，N，-二烷基氨基烷氧基羰基的新型2-氨基-1,4-二氢吡啶衍生物I，并在自发性高血压大鼠中评估了其降压作用。当叔氨基被引入1,4-二氢吡啶环的3-和/或5-酯侧链时，观察到抗高血压作用的持续时间显着延长。特别地，在3位含有环氨基的化合物比具有无环氨基的化合物显示出更高的效力。化学修饰研究表明，在3和5位的1,4-二氢吡啶的两个酯侧链可能以与抗高血压活性有关的不同方式起作用。

  DOI：

  10.1248/cpb.43.797
• 作为产物：
  描述：

  2-噻吩甲醛 、 N-甲基-2-羟基乙胺 在 sodium tetrahydroborate 作用下， 生成 2-[Methyl(2-thienylmethyl)amino]ethanol
  参考文献：
  名称：

  新型的2-氨基-1,4-二氢吡啶类钙拮抗剂。二。在3-和/或5-位具有N，N-二烷基氨基烷氧基羰基的2-氨基-1，4-二氢吡啶衍生物的合成和降压作用。

  摘要：

  合成了在3和/或5位上含有N，N，-二烷基氨基烷氧基羰基的新型2-氨基-1,4-二氢吡啶衍生物I，并在自发性高血压大鼠中评估了其降压作用。当叔氨基被引入1,4-二氢吡啶环的3-和/或5-酯侧链时，观察到抗高血压作用的持续时间显着延长。特别地，在3位含有环氨基的化合物比具有无环氨基的化合物显示出更高的效力。化学修饰研究表明，在3和5位的1,4-二氢吡啶的两个酯侧链可能以与抗高血压活性有关的不同方式起作用。

  DOI：

  10.1248/cpb.43.797

文献信息

• Multimodal Anion Exchange Matrices
  申请人：GE HEALTHCARE BIO-SCIENCES AB

  公开号：US20150299248A1

  公开（公告）日：2015-10-22

  The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R 1 -L 1 -N(R 3 )-L 2 -R, immobilized on a support, wherein R 1 is a five- or six-membered, substituted or non-substituted ring structure or a hydroxyethyl or hydroxypropyl group; L 1 is either a methylene group or a covalent bond; R 2 is a five- or six-membered, substituted or non-substituted ring structure; L 2 is either a methylene group or a covalent bond; R 3 is a methyl group; and wherein if R 1 is a hydroxyethyl group and L 1 is a covalent bond, R 2 is a substituted aromatic ring structure or a substituted or non-substituted aliphatic ring structure.

  该发明揭示了一种分离基质，包括多个分离配体，其由公式R1-L1-N(R3)-L2-R所定义，固定在支撑物上，其中R1是一个五元或六元的取代或非取代环结构或一个羟乙基或羟丙基基团；L1是一个亚甲基基团或一个共价键；R2是一个五元或六元的取代或非取代环结构；L2是一个亚甲基基团或一个共价键；R3是一个甲基基团；如果R1是一个羟乙基基团且L1是一个共价键，则R2是一个取代芳香环结构或一个取代或非取代脂环结构。
• Thiepino[3,2-b]dihydropyridines and related compositions and methods
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06420383B1

  公开（公告）日：2002-07-16

  This invention provides novel thiepino[3,2-b]dihydropyridines of the following formulae: These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity. Thus, this invention also provides pharmaceutical compositions, as well as methods, for preventing and treating disorders such as hypersensitivity, allergy, asthma, bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, urinary tract disorders, gastrointestinal motility disorders and cardiovascular disorders.

  本发明提供了以下式子的新型噻吩[3,2-b]二氢吡啶化合物：这些化合物可用作钙通道拮抗剂，具有心血管、抗哮喘和抗支气管收缩活性。因此，本发明还提供了用于预防和治疗过敏、过敏、哮喘、支气管痉挛、痛经、食管痉挛、青光眼、早产、泌尿系统疾病、胃肠道运动障碍和心血管疾病等疾病的制药组合物和方法。
• Multimodal anion exchange matrices
  申请人：GE Healthcare BioProcess R&D AB

  公开号：US10815269B2

  公开（公告）日：2020-10-27

  The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R1-L1-N(R3)-L2-R, immobilized on a support, wherein R1 is a five- or six-membered, substituted or non-substituted ring structure or a hydroxyethyl or hydroxypropyl group; L1 is either a methylene group or a covalent bond; R2 is a five-or six-membered, substituted or non-substituted ring structure; L2 is either a methylene group or a covalent bond; R3 is a methyl group; and wherein if R1 is a hydroxyethyl group and L1 is a covalent bond, R2 is a substituted aromatic ring structure or a substituted or non-substituted aliphatic ring structure.

  本发明公开了一种分离基质，它包括固定在支持物上的由式 R1-L1-N(R3)-L2-R 定义的多个分离配体，其中 R1 是五元或六元、取代或非取代的环结构或羟乙基或羟丙基；L1 是亚甲基或共价键；R2 是五元或六元、取代或非取代的环结构；L2 是亚甲基或共价键；R3 是甲基；如果 R1 是羟乙基，L1 是共价键，则 R2 是取代的芳环结构或取代或非取代的脂环结构。
• <i>N</i>-(2-Benzoylphenyl)-<scp>l</scp>-tyrosine PPARγ Agonists. 2. Structure−Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety
  作者：Jon L. Collins、Steven G. Blanchard、G. Evan Boswell、Paul S. Charifson、Jeff E. Cobb、Brad R. Henke、Emily A. Hull-Ryde、Wieslaw M. Kazmierski、Debra H. Lake、Lisa M. Leesnitzer、Jürgen Lehmann、James M. Lenhard、Lisa A. Orband-Miller、Yolanda Gray-Nunez、Derek J. Parks、Kelli D. Plunkett、Wei-Qin Tong

  DOI：10.1021/jm980413z

  日期：1998.12.1

  We previously reported the identification of (2S)-((2-benzoylphenyl)amino)-3-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl}propanoic (2) (PPAR gamma pK(i) = 8.94, PPAR gamma, pEC(50) = 9.47) as a potent and selective PPAR gamma agonist. We now report the expanded structure-activity relationship around the phenyl alkyl ether moiety by pursuing both a classical medicinal chemistry approach and a solid-phase chemistry approach for analogue synthesis. The solution-phase strategy focused on evaluating the effects of oxazole and phenyl ring replacements of the 2-(5-methyl-2-phenyloxazol-4-yl)ethyl side chain of 2 with several replacements providing potent and selective PPAR gamma agonists with improved aqueous solubility. Specifically, replacement of the phenyl ring of the phenyloxazole moiety with a 4-pyridyl group to give 2(S)-((2-benzoylphenyl)amino)-3-4-[2-(5-methyl-2-pyridin-4-yloxazol-4-yl)ethoxy]phenyl}propionic acid (16) (PPAR gamma pK(i) = 8.85, PPAR gamma pEC(50) = 8.74) or a 4-methylpiperazine to give 2(S)-((2-benzoylphenyl)amino)-3-(4-2-[5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl]ethoxy}pheynyl)propionic acid (24) (PPAR gamma pK(i) = 8.6, PPAR gamma pEC(50) = 8.89) provided two potent and selective PPAR gamma agonists with increased solubility in pH 7.4 phosphate buffer and simulated gastric fluid as compared to 2. The second strategy took advantage of the speed and ease of parallel solid-phase analogue synthesis to generate a more diverse set of phenyl alkyl ethers which led to the identification of a number of novel, high-affinity PPAR gamma ligands (PPAR gamma pK(i)'s 6.98-8.03). The combined structure-activity data derived from the two strategies provide valuable insight on the requirements for PPAR gamma binding, functional activity, selectivity, and aqueous solubility.
• 1,4-Dihydropyridines, leur procédé de préparation et leur application comme médicaments
  申请人：LABORATORIOS DELAGRANGE S.A.

  公开号：EP0302980B1

  公开（公告）日：1991-03-13